Volume 15, Issue 6, Pages (May 2014)

Slides:



Advertisements
Similar presentations
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast.
Advertisements

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials The Lancet Volume 386, Issue.
Volume 14, Issue 4, Pages (April 2013)
Volume 16, Issue 8, Pages (August 2015)
Volume 16, Issue 2, Pages (February 2015)
Volume 386, Issue 9988, Pages (July 2015)
Volume 18, Issue 6, Pages (June 2017)
Volume 376, Issue 9747, Pages (October 2010)
Volume 385, Issue 9985, Pages (June 2015)
Volume 11, Issue 4, Pages (April 2012)
Volume 15, Issue 6, Pages (May 2014)
Volume 17, Issue 2, Pages (February 2016)
Volume 14, Issue 10, Pages (September 2013)
Volume 14, Issue 4, Pages (April 2013)
Volume 377, Issue 9783, Pages (June 2011)
Volume 15, Issue 10, Pages (September 2014)
Volume 3, Issue 5, Pages (May 2016)
Volume 16, Issue 8, Pages (August 2015)
Volume 15, Issue 2, Pages (February 2014)
Volume 14, Issue 4, Pages (April 2015)
Effects of community health interventions on under-5 mortality in rural Guinea-Bissau (EPICS): a cluster-randomised controlled trial  Dr Peter Boone,
Volume 15, Issue 4, Pages (April 2014)
Volume 17, Issue 2, Pages (February 2016)
Volume 15, Issue 4, Pages (April 2014)
Volume 14, Issue 8, Pages (July 2013)
Volume 14, Issue 8, Pages (July 2013)
Volume 16, Issue 6, Pages (June 2015)
Volume 382, Issue 9900, Pages (October 2013)
Volume 18, Issue 3, Pages (March 2017)
Volume 379, Issue 9812, Pages (January 2012)
Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label,
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild- type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised.
Volume 387, Issue 10023, Pages (March 2016)
Effect of antenatal multiple micronutrient supplementation on anthropometry and blood pressure in mid-childhood in Nepal: follow-up of a double-blind.
Volume 14, Issue 6, Pages (May 2013)
Volume 20, Issue 1, Pages (January 2019)
Volume 373, Issue 9666, Pages (March 2009)
Volume 3, Issue 7, Pages (July 2016)
Volume 18, Issue 3, Pages (March 2017)
Volume 17, Issue 8, Pages (August 2016)
Volume 385, Issue 9985, Pages (June 2015)
Volume 19, Issue 4, Pages (April 2018)
Volume 15, Issue 8, Pages (July 2014)
Volume 15, Issue 12, Pages (November 2014)
Pre-entry screening programmes for tuberculosis in migrants to low-incidence countries: a systematic review and meta-analysis  Dr Robert W Aldridge, MSc,
Volume 373, Issue 9676, Pages (May 2009)
Volume 18, Issue 8, Pages (August 2017)
Volume 2, Issue 10, Pages e417-e426 (October 2015)
Volume 16, Issue 15, Pages (November 2015)
Volume 15, Issue 6, Pages (May 2014)
Volume 14, Issue 6, Pages (May 2013)
Volume 13, Issue 11, Pages (November 2012)
Volume 16, Issue 15, Pages (November 2015)
Volume 383, Issue 9932, Pages (May 2014)
Volume 16, Issue 8, Pages (August 2015)
Volume 14, Issue 8, Pages (July 2013)
Volume 386, Issue 10005, Pages (October 2015)
Volume 15, Issue 6, Pages (May 2014)
Volume 15, Issue 1, Pages (January 2014)
Volume 15, Issue 8, Pages (July 2014)
Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial  Dr David Preiss, PhD, Suzanne M Lloyd,
Volume 11, Issue 1, Pages (January 2010)
Volume 2, Issue 10, Pages (October 2015)
Volume 18, Issue 10, Pages (October 2017)
Volume 376, Issue 9747, Pages (October 2010)
DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter.
Volume 20, Issue 5, Pages (May 2019)
Volume 388, Issue 10042, Pages (July 2016)
Volume 14, Issue 7, Pages (June 2013)
Volume 17, Issue 2, Pages (February 2016)
Presentation transcript:

Volume 15, Issue 6, Pages 620-630 (May 2014) Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study  Dr Pippa G Corrie, PhD, Andrea Marshall, PhD, Prof Janet A Dunn, PhD, Prof Mark R Middleton, PhD, Paul D Nathan, PhD, Prof Martin Gore, PhD, Prof Neville Davidson, FRCP, Steve Nicholson, PhD, Charles G Kelly, FRCR, Maria Marples, PhD, Sarah J Danson, PhD, Ernest Marshall, MD, Stephen J Houston, MD, Ruth E Board, PhD, Ashita M Waterston, PhD, Jenny P Nobes, FRCR, Mark Harries, PhD, Satish Kumar, MD, Gemma Young, MPhil, Paul Lorigan, MD  The Lancet Oncology  Volume 15, Issue 6, Pages 620-630 (May 2014) DOI: 10.1016/S1470-2045(14)70110-X Copyright © 2014 Corrie et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 1 Trial profile HR=hazard ratio. *Patients were included in the longitudinal quality-of-life analysis if they had completed at least two questionnaires. The Lancet Oncology 2014 15, 620-630DOI: (10.1016/S1470-2045(14)70110-X) Copyright © 2014 Corrie et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 2 Overall survival (A) and distant metastasis-free interval (B), analysis unadajusted for stratification factors HR=hazard ratio. The Lancet Oncology 2014 15, 620-630DOI: (10.1016/S1470-2045(14)70110-X) Copyright © 2014 Corrie et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 3 Disease-free interval for all patients (A), for patients with a BRAF mutation (B), and for those with BRAF wild type (C) HR=hazard ratio. The Lancet Oncology 2014 15, 620-630DOI: (10.1016/S1470-2045(14)70110-X) Copyright © 2014 Corrie et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 4 Hazard ratio plot of the treatment effect by prognostic factors for disease-free interval O–E=observed–expected events. HR=hazard ratio. The Lancet Oncology 2014 15, 620-630DOI: (10.1016/S1470-2045(14)70110-X) Copyright © 2014 Corrie et al. Open Access article distributed under the terms of CC BY Terms and Conditions